九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Hongzhou Investment, plans to invest in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) with a total subscription amount of 77 million yuan, where Hongzhou Investment will contribute 10 million yuan, accounting for 12.987% of the total subscription amount [1] Group 1: Investment Details - The total subscription amount for the partnership is 77 million yuan, which includes this investment [1] - Hongzhou Investment will act as a limited partner and will contribute 10 million yuan of its own funds [1] - Hongzhou Investment's contribution represents 12.987% of the total subscription amount for the partnership [1] Group 2: Investment Focus - The partnership will primarily invest in new drug research and development, as well as medical device research projects within the pharmaceutical sector [1] - Investment targets include high-quality emerging medical enterprises, which encompass new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development companies [1]